A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study.
Phase of Trial: Phase III
Latest Information Update: 27 Aug 2017
At a glance
- Drugs Abiraterone acetate (Primary)
- Indications Advanced breast cancer; Prostate cancer
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 01 Mar 2017 Status changed from active, no longer recruiting to recruiting.
- 11 May 2015 Planned End Date changed from 1 Apr 2015 to 1 Apr 2018 as reported by ClinicalTrials.gov record.
- 11 May 2015 Planned primary completion date changed from 1 Apr 2015 to 1 Apr 2018 as reported by ClinicalTrials.gov record.